Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lear Corporation stock logo
LEA
Lear
$103.28
+0.1%
$98.10
$73.85
$119.10
$5.49B1.3714,237 shs274,126 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$82.82
+0.1%
$80.97
$73.31
$120.30
$206.85B0.3815.52 million shs5.95 million shs
Novartis AG stock logo
NVS
Novartis
$122.43
+1.0%
$118.45
$96.06
$124.83
$258.70B0.621.99 million shs635,199 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$152.49
+0.0%
$155.57
$139.70
$200.33
$67.55B0.883.11 million shs1.43 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lear Corporation stock logo
LEA
Lear
+3.23%+8.47%-3.83%+10.06%-7.26%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.96%+4.11%-1.25%+10.70%-27.73%
Novartis AG stock logo
NVS
Novartis
+1.62%+6.80%+0.17%+11.90%+7.77%
Zoetis Inc. stock logo
ZTS
Zoetis
+1.78%+3.92%-2.12%-4.92%-19.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lear Corporation stock logo
LEA
Lear
4.912 of 5 stars
3.25.02.50.91.32.54.4
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9971 of 5 stars
3.25.05.04.23.11.73.8
Novartis AG stock logo
NVS
Novartis
1.6578 of 5 stars
1.03.02.50.02.80.01.9
Zoetis Inc. stock logo
ZTS
Zoetis
4.9215 of 5 stars
3.35.04.20.44.02.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lear Corporation stock logo
LEA
Lear
2.31
Hold$113.009.41% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.35
Hold$107.4429.72% Upside
Novartis AG stock logo
NVS
Novartis
2.09
Hold$123.500.87% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
2.50
Moderate Buy$202.4332.75% Upside

Current Analyst Ratings Breakdown

Latest LEA, NVS, ZTS, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$210.00 ➝ $215.00
8/8/2025
Novartis AG stock logo
NVS
Novartis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$123.00
7/30/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $90.00
7/28/2025
Lear Corporation stock logo
LEA
Lear
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$116.00 ➝ $109.00
7/17/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$180.00 ➝ $155.00
7/16/2025
Lear Corporation stock logo
LEA
Lear
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $120.00
7/14/2025
Lear Corporation stock logo
LEA
Lear
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$95.00 ➝ $116.00
7/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.00
7/1/2025
Lear Corporation stock logo
LEA
Lear
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $103.00
6/30/2025
Lear Corporation stock logo
LEA
Lear
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$123.00 ➝ $136.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lear Corporation stock logo
LEA
Lear
$23.31B0.24$25.38 per share4.07$97.93 per share1.05
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.22$9.77 per share8.48$19.64 per share4.22
Novartis AG stock logo
NVS
Novartis
$50.32B5.14$10.98 per share11.15$19.91 per share6.15
Zoetis Inc. stock logo
ZTS
Zoetis
$9.26B7.30$7.20 per share21.18$11.23 per share13.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lear Corporation stock logo
LEA
Lear
$506.60M$8.5712.056.900.612.05%13.94%4.63%10/23/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4912.768.370.8525.79%41.05%16.55%10/30/2025 (Estimated)
Novartis AG stock logo
NVS
Novartis
$11.94B$6.8717.8313.901.6725.64%41.08%16.83%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.49B$5.8126.2322.592.4427.83%56.90%19.54%N/A

Latest LEA, NVS, ZTS, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.62$1.76+$0.14$1.61$2.41 billion$2.46 billion
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
7/25/2025Q2 2025
Lear Corporation stock logo
LEA
Lear
$3.23$3.47+$0.24$3.06$5.89 billion$6.03 billion
7/17/2025Q2 2025
Novartis AG stock logo
NVS
Novartis
$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lear Corporation stock logo
LEA
Lear
$3.082.98%N/A35.94%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.91%N/A49.92%14 Years
Novartis AG stock logo
NVS
Novartis
$2.602.12%N/A37.85%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.001.31%N/A34.42%14 Years

Latest LEA, NVS, ZTS, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.97%9/15/20259/15/202510/7/2025
5/22/2025
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.501.2%7/18/20257/18/20259/3/2025
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
5/16/2025
Lear Corporation stock logo
LEA
Lear
quarterly$0.773.25%6/5/20256/5/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lear Corporation stock logo
LEA
Lear
0.53
1.34
1.07
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17
Novartis AG stock logo
NVS
Novartis
0.53
0.82
0.62
Zoetis Inc. stock logo
ZTS
Zoetis
1.05
1.76
1.04

Institutional Ownership

CompanyInstitutional Ownership
Lear Corporation stock logo
LEA
Lear
97.04%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Lear Corporation stock logo
LEA
Lear
0.91%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Novartis AG stock logo
NVS
Novartis
0.01%
Zoetis Inc. stock logo
ZTS
Zoetis
0.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lear Corporation stock logo
LEA
Lear
173,70053.21 million52.72 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.49 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,8832.11 billion2.11 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
13,800443.18 million442.39 millionOptionable

Recent News About These Companies

Rathbones Group PLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)
Piper Sandler Keeps Their Buy Rating on Zoetis (ZTS)
Zoetis Inc. (NYSE:ZTS) Shares Sold by Gouws Capital LLC
Invesco Ltd. Acquires 44,977 Shares of Zoetis Inc. (NYSE:ZTS)
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Nuveen LLC Invests $616.38 Million in Zoetis Inc. (NYSE:ZTS)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Lear stock logo

Lear NYSE:LEA

$103.28 +0.05 (+0.05%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lear Corporation designs, develops, engineers, manufactures, assembles, and supplies automotive seating, and electrical distribution systems and related components for automotive original equipment manufacturers in North America, Europe, Africa, Asia, and South America. Its Seating segment offers seat systems, seat subsystems, keyseat components, seat trim covers, seat mechanisms, seat foams, and headrests, as well as surface materials, such as leather and fabric for automobiles and light trucks, compact cars, pick-up trucks, and sport utility vehicles. The company's E-Systems segment provides electrical distribution and connection systems that route electrical signals and networks; and manage electrical power within the vehicle for various powertrains. This segment's products comprise wire harnesses, terminals and connectors, engineered components, and junction boxes; electronic system products, including body domain control modules, smart and passive junction boxes, gateway and communication modules, integrated power modules, and high voltage switching and power control systems. It also offers software and connected services comprising Xevo Market, an in-vehicle commerce and service platform; and software and services for the cloud, vehicles, and mobile devices. In addition, this segment provides cybersecurity software; advanced vehicle positioning for automated and autonomous driving applications; and short-range communication and cellular protocols for vehicle connectivity. It offers its products and services under the XEVO, GUILFORD, EAGLE OTTAWA, ConfigurE+, INTUTM, LEAR CONNEXUSTM, EXO, JOURNEYWARE, ProTec, SMART JUNCTION BOX, STRUCSURE, AVENTINO, and TeXstyle brands. Lear Corporation was founded in 1917 and is headquartered in Southfield, Michigan.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$82.82 +0.11 (+0.14%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$122.43 +1.23 (+1.02%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Zoetis stock logo

Zoetis NYSE:ZTS

$152.49 +0.05 (+0.03%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.